Gyre Therapeutics, Inc. (GYRE)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
6.34 USD
-0.18
(-2.761%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 6.35 +0.01 (0.158%) ⇧ (July 13, 2026, 7:25 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 2:36 a.m. EDT
Gyre Therapeutics presents a stark dichotomy between its pristine balance sheet and its catastrophic long-term performance. Fundamentally, the company is a fortress: it holds nearly $50 million in cash against negligible debt, boasts a massive 4.6x current ratio, and maintains industry-leading gross margins of 95%. This financial health is undeniable. However, the market has overwhelmingly rejected this business, evidenced by a 97% cumulative decline over the last nine years and a trailing twelve-month loss. The recent addition to defensive indices likely reflects this safety in assets rather than optimism for growth, as revenue growth remains stagnant at just 2%. The stock is trading at a premium multiple despite negative earnings, a classic value trap where the market prices in permanent impairment. While the balance sheet prevents bankruptcy, the lack of a credible path to profitability and the persistent multi-year downtrend suggest the core business model is failing to generate value. The options market confirms this pessimism, with traders hedging downside rather than betting on a turnaround. Until there is a clear catalyst for revenue acceleration or a profitable milestone, the risk of capital destruction outweighs the safety of the cash pile. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.189181 |
| AutoTheta | 0.206748 |
| AutoETS | 0.209210 |
| MSTL | 0.210793 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.13 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.176 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2023-01-12 |
| Debt to Equity Ratio | 0.601 |
| Revenue per Share | 1.292 |
| Market Cap | 706,839,296 |
| Forward P/E | 105.67 |
| Beta | 4.78 |
| Profit Margins | -5.44% |
| Website | https://www.gyretx.com |
As of July 11, 2026, 2:36 a.m. EDT: Speculators are positioning defensively with heavy put open interest at deep strikes ($2.50), suggesting a fear of further downside or a desire to cap losses. Conversely, call activity is sparse and concentrated at out-of-the-money strikes ($10.00), indicating limited bullish conviction. Implied volatility is extremely low for both calls and puts, reflecting a lack of active speculation and a 'wait-and-see' sentiment rather than a directional bet.
| Date | Dividend | Yield % |
|---|---|---|
| 2023-01-13 | 3.600 | 92.307690 |
| 2022-09-21 | 21.450 | 286.000000 |
| 2015-08-20 | 896.175 | 59.270833 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.14323258 |
| Address1 | 12,730 High Bluff Drive |
| Address2 | Suite 250 |
| All Time High | 47,990.25 |
| All Time Low | 2.85 |
| Ask | 8.12 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 166,010 |
| Average Daily Volume3 Month | 94,734 |
| Average Volume | 94,734 |
| Average Volume10Days | 166,010 |
| Beta | 4.775 |
| Bid | 4.58 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 1.109 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.34 |
| Current Ratio | 4.636 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.49 |
| Day Low | 6.31 |
| Debt To Equity | 0.601 |
| Display Name | Gyre Therapeutics |
| Dividend Date | 1,673,481,600 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | 5,073,000 |
| Ebitda Margins | 0.04334 |
| Enterprise To Ebitda | 111.569 |
| Enterprise To Revenue | 4.835 |
| Enterprise Value | 565,989,120 |
| Eps Forward | 0.06 |
| Eps Trailing Twelve Months | -0.08 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.5432 |
| Fifty Day Average Change | -0.20319986 |
| Fifty Day Average Change Percent | -0.03105512 |
| Fifty Two Week Change Percent | -14.323258 |
| Fifty Two Week High | 9.42 |
| Fifty Two Week High Change | -3.08 |
| Fifty Two Week High Change Percent | -0.3269639 |
| Fifty Two Week Low | 5.44 |
| Fifty Two Week Low Change | 0.9000001 |
| Fifty Two Week Low Change Percent | 0.16544119 |
| Fifty Two Week Range | 5.44 - 9.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,144,848,600,000 |
| Float Shares | 33,927,316 |
| Forward Eps | 0.06 |
| Forward P E | 105.66667 |
| Free Cashflow | 9,599,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 625 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.95088 |
| Gross Profits | 111,300,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.86334 |
| Held Percent Institutions | 0.03751 |
| Implied Shares Outstanding | 111,488,849 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,673,568,000 |
| Last Dividend Value | 3.6 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,698,710,400 |
| Last Split Factor | 1:15 |
| Long Business Summary | Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc. |
| Long Name | Gyre Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 706,839,296 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_100542295 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -6,362,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 725,792,406 |
| Number Of Analyst Opinions | 3 |
| Open | 6.41 |
| Operating Cashflow | 4,319,000 |
| Operating Margins | -0.30206 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 858-284-0115 |
| Post Market Change | 0.009999752 |
| Post Market Change Percent | 0.1577248 |
| Post Market Price | 6.35 |
| Post Market Time | 1,783,985,101 |
| Previous Close | 6.52 |
| Price Hint | 2 |
| Price To Book | 5.716862 |
| Price To Sales Trailing12 Months | 6.038832 |
| Profit Margins | -0.05435 |
| Quick Ratio | 3.679 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.18 |
| Regular Market Change Percent | -2.76073 |
| Regular Market Day High | 6.49 |
| Regular Market Day Low | 6.31 |
| Regular Market Day Range | 6.31 - 6.49 |
| Regular Market Open | 6.41 |
| Regular Market Previous Close | 6.52 |
| Regular Market Price | 6.34 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 64,819 |
| Return On Assets | 0.01035 |
| Return On Equity | -0.030769998 |
| Revenue Growth | 0.021 |
| Revenue Per Share | 1.292 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 111,488,849 |
| Shares Percent Shares Out | 0.0164 |
| Shares Short | 1,826,634 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,672,318 |
| Short Name | Gyre Therapeutics, Inc. |
| Short Percent Of Float | 0.0519 |
| Short Ratio | 14.73 |
| Source Interval | 15 |
| State | CA |
| Symbol | GYRE |
| Target High Price | 20.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 18.66667 |
| Target Median Price | 18.0 |
| Total Cash | 49,808,000 |
| Total Cash Per Share | 0.545 |
| Total Debt | 823,000 |
| Total Revenue | 117,049,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.4126 |
| Two Hundred Day Average Change | -1.0725999 |
| Two Hundred Day Average Change Percent | -0.14469954 |
| Type Disp | Equity |
| Volume | 64,819 |
| Website | https://www.gyretx.com |
| Zip | 92,130 |